

# News release

## **Kyowa Kirin Announces Establishing New Biologics Manufacturing Plant in North Carolina, in the United States**

- *Company's first manufacturing facility in North America designed to accelerate development and production of new biologic therapies to advance clinical pipeline*

Tokyo, Japan, June 10, 2024 --Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin") announced establishing a new, state-of-the-art manufacturing facility in Sanford, North Carolina, in the United States. Kyowa Kirin will invest up to \$530M in the construction of a 15,951m<sup>2</sup> (171,700-square-foot), two-bioreactor facility, scheduled to break ground in Q3 of 2024. The new facility will accelerate Kyowa Kirin's development and production of biologic therapies for patients with debilitating diseases that have unmet medical needs.

"I am very excited to announce that Kyowa Kirin decided to construct a new manufacturing plant for biologics drug substance in the United States," said Toshiyuki Kurata, Chief Supply Chain Officer, and Global Manufacturing Head at Kyowa Kirin. "The new facility will be scalable with our Takasaki Plant, to help ease technology transfer between the two plants and add production capacity. We believe this will help accelerate drug development and production."

The new facility will manufacture innovative biologic therapies, including next-generation antibodies, for Kyowa Kirin's planned clinical trials and future commercial use while creating more resilient and efficient supply lines that more readily withstand shifting global forces. Additional land will allow for future expansion, should the company's portfolio necessitate greater capacity as its pipeline programs advance.



Digital images of the new plant

“Our North American presence continues to grow through strategic investments that are adding new capabilities, new therapeutic expertise, and new talent to our global organization, all in service of meeting patients’ needs,” said Steve Schaefer, President, North America.

“Among the many qualities that drew us to North Carolina are our shared values, such as harmony and teamwork—known as *Wa*, which is deeply engrained in our culture at Kyowa Kirin, evident in our longstanding corporate partnerships, and fundamental to high-quality product manufacturing.”

The Sanford facility will round out Kyowa Kirin’s global manufacturing network, which includes sites in Takasaki City, Gunma Prefecture, and Ube City, Yamaguchi Prefecture in Japan. The new facility will build upon the manufacturing methods and technologies in the Takasaki plant to further enhance the company’s productivity and efficiency. By locating its new site in the midst of North Carolina’s robust life sciences hub, Kyowa Kirin will benefit from a thriving network of biomanufacturing resources as well as a rich pool of talent within the greater Research Triangle Park region, the largest research park in the United States.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

**【Building overview】**

Location	Sanford, North Carolina, United States
Scale	Gross floor area; 15,951 m <sup>2</sup> (171,700-square-foot), 2-bioreactors
Land area	303,514 m <sup>2</sup>
Investment amount	Up to \$530M
Start to construct	2024 H2(planned)
Completion	2027(planned)
Features	Manufacturing innovative biologic therapies including next-generation antibodies